I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EL 984097164 US, in an envelope addressed to: MS RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: September 19, 2005

Signature: (Norman Sreen)

Patent Docket No. 219002028310

SEP 1 9 2005

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Tre Patent Application of: Babu J. MAVUNKEL et al.

Serial No.: 10/076,131

Filing Date: February 13, 2002

For: COMPOUNDS AND METHODS TO

TREAT CARDIAC FAILURE AND

OTHER DISORDERS

Examiner: C. Chang

Group Art Unit: 1625

## INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98

MS RCE Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO/SB/08a/b. Copies of non-patent literature documents numbered 31, 35, 39, 49, and 62 are submitted herewith. However, copies of the remaining documents cited in the attached Form PTO/SB/08a/b were previously submitted in an Information Disclosure Statement and/or Office Action, directed to the related applications: Serial Number 09/316,761, filed May 21, 1999, now United States Patent Number 6,589,954, and Serial Number 09/275,176, filed March 24, 1999, now United States Patent Number 6,340,685, and Serial Number 09/128,137, filed August 3, 1998, now United States Patent Number 6,130,235, and, accordingly, copies are not included herewith. This protocol conforms with 37

C.F.R. §1.98(d) and M.P.E.P. 609(A)(2). The Examiner is requested to make these documents of record in the application.

This Information Disclosure Statement is submitted:

	With t	he application; accordingly, no fee or separate requirements are required.
$\boxtimes$	Before	e the mailing of a first Office Action after the filing of a Request for Continued
	Exam	ination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97
	(e)(1)	has been provided.
	Within	n three months of the application filing date or before mailing of a first Office Action
	on the	merits; accordingly, no fee or separate requirements are required. However, if
	applic	able, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.
	After	receipt of a first Office Action on the merits but before mailing of a final Office Action
	or Not	tice of Allowance.
		A fee is required. A check in the amount of is enclosed.
		A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to
		this submission in duplicate.
		A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly; no fee is
		believed to be due.
	After	mailing of a final Office Action or Notice of Allowance, but before payment of the
	issue f	ee.
		A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the
		amount of is enclosed.
		A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal
		form (PTO/SB/17 is attached to this submission in duplicate.)

Applicants would appreciate the Examiner initialing and returning the Form PTO/SB/08a/b, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent and Trademark Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. § 1.17 (p)) is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petition and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 219002028310.

Dated: September 19, 2005

Respectfully submitted,

Michael G. Smith

Registration No.: 44,422

MORRISON & FOERSTER LLP

3811 Valley Centre Drive

Suite 500

San Diego, California 92130-2332

(858) 720-5100



## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of

Complete if Known				
Application Number	10/076,131			
Filing Date	February 13, 2002			
First Named Inventor	Babu J. MAVUNKEL			
Art Unit	1625			
Examiner Name	C. Chang			
Attorney Docket Number	219002028310			

			U.S. PA	TENT DOCUMENTS	
Examiner	Cite		Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant
Initials*	No.1	Number-Kind Code <sup>2</sup> (if known)	MM-DD-YYYY	Applicant of Cited Document	Figures Appear
	1.	US-4,088,765	05-09-1978	Winn et al.	
	2.	US-4,243,806	01-06-1981	Raeymaekers et al.	
	3.	US-4,454,130	06-12-1984	Tominaga et al.	
	4.	US-4,600,715	07-15-1986	Huth et al.	
	5.	US-4,737,501	04-12-1988	Tominago et al.	
	6.	US-4,886,809	12-12-1989	Tamada et al.	
	7.	US-4,937,246	06-26-1990	Sugihara et al.	
	8.	US-5,462,934	10-31-1995	Goto et al.	•
	9.	US-5,698,553	12-16-1997	Prucher et al.	
	10.	US-5,714,498	02-03-1998	Kulagowski et al.	
	11.	US-5,726,177	03-10-1998	Halazy et al.	
	12.	US-5,795,907	08-18-1998	Kalindjian et al.	
	13.	US-5,817,871	10-06-1998	Dingerdissen et al.	
	14.	US-6,589,954	07-08-2003	Mavunkel et al.	

	FOREIGN PATENT DOCUMENTS					
Examiner	Cite	Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages	
Initials*	No.1	Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	MM-DD-YYYY	Applicant of Cited Document	or Relevant Figures Appear	
	15.	EP-0 318 235	05/1989			
	16.	EP-0 431 945	06/1991			
	17.	EP-0 709 384	05/1996			
	18.	EP-0 831 090	03/1998			
	19.	JP-2-184673	07/1990			
	20.	JP-3-161470	07/1991			
	21.	WO-96/40143	12/1996			
	22.	WO-97/26252	07/1997			
	23.	WO-98/06715	02/1998			
	24.	WO-98/07425	02/1998			
	25.	WO-98/28292	07/1998			$\Box$
	26.	WO-99/61426	12/1999			
	27.	WO-00/12074	03/2000			

\*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at <a href="www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁵ Applicant is to place a check mark here if English language Translation is attached.

Examiner	Date	
Signature	Considered	



## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 2

Complete if Known				
Application Number	10/076,131			
Filing Date	February 13, 2002			
First Named Inventor	Babu J. MAVUNKEL			
Art Unit	1625			
Examiner Name	C. Chang			
Attorney Docket Number	219002028310			

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	28.	ADAMS et al., CA (1998) 128:201066	
	29.	CEGLA et al., CA (1996) 126:31297	
	30.	DE CLERCK et al., Throm. Res. (1981) 23:1-12	
	31.	DINARELLO, Chest (2000) 118(2):503-508	
	32.	DUKIC et al., Arch. Pharm. (1997) 330:25-28	
	33.	EYERS et al., Chem. and Biol. (1995) 5:321-328	L
	34.	FISCHER, CA (1996) 67:10051	
	35.	Foye's Principles of Medicinal Chemistry, 5th ed., (2002) pp. 56-57	
	36.	GASSMAN, J. Am. Chem. Soc. (1974) 96(17):5495-5508	
	37.	GOEHRING et al., CA (2000) 132:203174	
	38.	HARBESON et al., CA (1988) 109:162909	
	39.	HASHIMOTO et al., Clinical and Experimental Allergy (1999-2000) 30:48-55	
	40.	International Search Report dated July 29, 1999	
	41.	JIANG et al., J. Biol. Chem. (1996) 271:17920-17926	
	42.	KUMAR et al., Biochem. Biophys. Res. Comm. (1997) 235:533-538	I
	43.	LI et al., Biochem. Biophys. Res. Comm. (1996) 228:334-340	
	44.	MAGUIRE et al., CA (1979) 92:122605	
	45.	MITTENDORF et al., CA (2000) 132:265195	
	46.	MURAI et al., Heterocycles (1992) 34(5):1017-1029	Ţ
	47.	NAKAI et al., CA (1994) 121:222012	
	48.	NAKAI et al., CA (1994) 121:221997	
	49.	NICK et al., J. Clin. Invest. (1997) 99:975-986	
	50.	OELSCHLAEGER et al., CA (1988) 109:73387	
	51.	OGAWA et al., CA (1988) 110:57613	
	52.	OTSUKA PHARM., CA (1983) 100:51465	
	53.	OTSUKA PHARM., CA (1983) 100:34414	_
	54.	OTSUKA PHARM., CA (1984) 100:68187	
	55.	SCHMIT et al., CA (1994) 122:53913	
	56.	SOCIETE DES USINE CHEMIQUES, CA (1968) 77:34584	
	57.	STEIN et al., J. Biol. Chem. (1997) 272:19509-19517	
	58.	TAMADA et al., CA (1989) 111:53834	
	59.	VON STRANDTMANN, CA (1971) 80:82713	
	60.	WANG et al., J. Biol. Chem. (1997) 272:23668-23674	$\prod$
	61.	WANG et al., J. Biol. Chem. (1998) 273:2161-2168	
	62.	YIN et al., Nature (1998) 396:77-80	

<sup>\*</sup>EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	Date	
	Date	
Signature	Considered	

<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.